GLOBAL PANIC ATTACK TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Global Panic Attack Treatment Market, By Drug Class (Antidepressants, Anti-anxiety Drugs, CGRP Antagonists, Others), By Route of Administration (Oral, Intravenous, Intramuscular, Sublingual, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Global Panic Attack Treatment Market- Recent Developments

On April 26, 2023, Sunovion Pharmaceuticals Inc., a pharmaceutical company, and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka), a global healthcare company, announced that the first patient has been enrolled in a Phase 2/3 clinical study evaluating ulotaront, a trace amine-associated receptor 1 (TAAR1) agonist with 5-HT1A agonist activity, for the treatment of generalized anxiety disorder (GAD)
On February 14, 2023, PureTech Health plc., a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, announced that it will advance LYT-300 (oral allopregnanolone) for the potential treatment of anxiety disorders and postpartum depression (PPD)
On November 30, 2022, ANANDA Scientific Inc., a research focused bio-pharmaceutical company, announced that it had received approval from the U.S. Food and Drug Administration (FDA) of the IND application for a clinical trial evaluating Nantheia A1002N5S, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary Liquid Structure delivery technology as a potential treatment for Social Anxiety Disorder
On December 16, 2022, AbbVie, a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved VRAYLAR (cariprazine) as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults